FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 327:1842-1848 December 24, 1992 Number 26 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Pneumocystis carinii pneumonia (PCP) continues to be the most common index diagnosis in the acquired immunodeficiency syndrome (AIDS), but it is not clear which of several available agents is the most effective in preventing a recurrence of PCP. METHODS. We conducted a comparative, open-label trial in 310 adults with AIDS who had recently recovered from an initial episode of PCP and had no treatment-limiting toxic effects of trimethoprim-sulfamethoxazole or pentamidine. All the patients were treated with zidovudine and were randomly assigned to receive either 800 mg of sulfamethoxazole and 160 mg of trimethoprim once daily or 300 mg of aerosolized pentamidine administered every four weeks by jet nebulizer. The participants were followed for a median of 17.4 months. RESULTS. In the trimethoprim-sulfamethoxazole group (n = 154) there were 14 recurrences of PCP, as compared with 36 recurrences (including 1 extrapulmonary recurrence) in the aerosolized-pentamidine group (n = 156). The estimated recurrence rates at 18 months were 11.4 percent with trimethoprim-sulfamethoxazole and 27.6 percent with pentamidine (P < 0.001). The risk of a recurrence (adjusted for initial CD4 cell count) was 3.25 times higher in the pentamidine group (P < 0.001, 95 percent confidence interval, 1.72 to 6.16). There were no significant differences between the groups in survival or in hematologic or hepatic toxicity. Crossovers from trimethoprim-sulfamethoxazole to aerosolized pentamidine were more common than the reverse (27 vs. 4 percent), partly because of the study protocols for the management of leukopenia. There were 19 serious bacterial infections in the trimethoprim-sulfamethoxazole group and 38 in the pentamidine group. The time to a first bacterial infection was significantly greater for those assigned to trimethoprim-sulfamethoxazole (P = 0.017). CONCLUSIONS. In patients with AIDS who are receiving zidovudine, trimethoprim-sulfamethoxazole is more effective than aerosolized pentamidine in conventional doses for the prevention of recurrent pneumocystis infection.

Source Information

Department of Medicine, University of California, Los Angeles.

This article has been cited by other articles:

• Davis, J L, Welsh, D A, Beard, C B, Jones, J L, Lawrence, G G, Fox, M R, Crothers, K, Morris, A, Charbonnet, D, Swartzman, A, Huang, L (2008). Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia. Thorax 63: 329-334 [Abstract] [Full Text]  
• Rodriguez, M., Fishman, J. A. (2004). Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients. Clin. Microbiol. Rev. 17: 770-782 [Abstract] [Full Text]  
• Lytle, D., Frietch, C., Covert, T. (2004). Electrophoretic Mobility of Mycobacterium avium Complex Organisms. Appl. Environ. Microbiol. 70: 5667-5671 [Abstract] [Full Text]  
• Masters, P. A., O'Bryan, T. A., Zurlo, J., Miller, D. Q., Joshi, N. (2003). Trimethoprim-Sulfamethoxazole Revisited. Arch Intern Med 163: 402-410 [Abstract] [Full Text]  
• Masur, P. b. H., Kaplan, J. E., Holmes, K. K. (2002). Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. ANN INTERN MED 137: 435-478 [Abstract] [Full Text]  
• Taggart, S., Breen, R., Goldsack, N., Sabin, C., Johnson, M., Lipman, M. (2002). The Changing Pattern of Bronchoscopy in an HIV-Infected Population*. Chest 122: 878-885 [Abstract] [Full Text]  
• Mayaud, C., Parrot, A., Cadranel, J. (2002). Pyogenic bacterial lower respiratory tract infection in human immunodeficiency virus-infected patients. Eur Respir J 20: 28S-39s [Abstract] [Full Text]  
• Baggish, A. L., Hill, D. R. (2002). Antiparasitic Agent Atovaquone. Antimicrob. Agents Chemother. 46: 1163-1173 [Full Text]  
• Goldie, S. J., Kaplan, J. E., Losina, E., Weinstein, M. C., Paltiel, A. D., Seage III, G. R., Craven, D. E., Kimmel, A. D., Zhang, H., Cohen, C. J., Freedberg, K. A. (2002). Prophylaxis for Human Immunodeficiency Virus-Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines. Arch Intern Med 162: 921-928 [Abstract] [Full Text]  
• Wininger, D. A., Fass, R. J. (2002). Impact of Trimethoprim-Sulfamethoxazole Prophylaxis on Etiology and Susceptibilities of Pathogens Causing Human Immunodeficiency Virus-Associated Bacteremia. Antimicrob. Agents Chemother. 46: 594-597 [Abstract] [Full Text]  
• Tiemessen, C. T., Shalekoff, S., Meddows-Taylor, S., Martin, D. J. (2001). Antituberculosis Treatment: Increasing Evidence for Drug Effects on Innate Cellular Immunity. CVI 8: 686-689 [Full Text]  
• MAYAUD, C, CADRANEL, J (2001). AIDS and the lung in a changing world. Thorax 56: 423-426 [Full Text]  
• Wei, C. C-Y, Gardner, S., Rachlis, A., Pack, L. L., Chan, C. K. N. (2001). Risk Factors for Prophylaxis Failure in Patients Receiving Aerosol Pentamidine for Pneumocystis carinii Pneumonia Prophylaxis. Chest 119: 1427-1433 [Abstract] [Full Text]  
• Albert, J. M, Yun, H. (2001). Statistical advances in AIDS therapy trials. Stat Methods Med Res 10: 85-100 [Abstract]  
• de Quiros, J. C. L. B., Miro, J. M., Pena, J. M., Podzamczer, D., Alberdi, J. C., Martinez, E., Cosin, J., Claramonte, X., Gonzalez, J., Domingo, P., Casado, J. L., Ribera, E., The Grupo de Estudio del SIDA 04/98, (2001). A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis against Pneumocystis carinii Pneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection. NEJM 344: 159-167 [Abstract] [Full Text]  
• Ledergerber, B., Mocroft, A., Reiss, P., Furrer, H., Kirk, O., Bickel, M., Uberti-Foppa, C., Pradier, C., d'Arminio Monforte, A., Schneider, M. M.E., Lundgren, J. D. (2001). Discontinuation of Secondary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. NEJM 344: 168-174 [Abstract] [Full Text]  
• Girard, P.-M. (2001). Discontinuing Pneumocystis carinii Prophylaxis. NEJM 344: 222-223 [Full Text]  
• Purdy, B. D. (2000). Management and Prevention of Opportunistic Infections in the HIV-Infected Patient. Journal of Pharmacy Practice 13: 475-498 [Abstract]  
• Freund, Y. R., Dousman, L., MacGregor, J. T., Mohagheghpour, N. (2000). Oral Treatment with Trimethoprim-Sulfamethoxazole and Zidovudine Suppresses Murine Accessory Cell-Dependent Immune Responses. Toxicol Sci 55: 335-342 [Abstract] [Full Text]  
• Kovacs, J. A., Masur, H. (2000). Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. NEJM 342: 1416-1429 [Full Text]  
• USPHS/IDSA Prevention of Opportunistic Infections, (1999). 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. ANN INTERN MED 131: 873-908 [Full Text]  
• Covert, T. C., Rodgers, M. R., Reyes, A. L., Stelma, G. N. Jr. (1999). Occurrence of Nontuberculous Mycobacteria in Environmental Samples. Appl. Environ. Microbiol. 65: 2492-2496 [Abstract] [Full Text]  
• Fishman, J. A. (1998). Prevention of Infection Due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42: 995-1004 [Full Text]  
• Owens, D. K., Brandeau, M. L., Sox, C. H. (1998). Effect of Relapse to High-Risk Behavior on the Costs and Benefits of a Program to Screen Women for Human Immunodeficiency Virus. Interfaces 28: 52-74 [Abstract]  
• Paltiel, A. D., Scharfstein, J. A., Seage, G. R., Losina, E., Goldie, S. J., Weinstein, M. C., Craven, D. E., Freedberg, K. A. (1998). A Monte Carlo Simulation of Advanced HIV Disease: Application to Prevention of CMV Infection. Med Decis Making 18: S93-S105 [Abstract]  
• Freedberg, K. A., Scharfstein, J. A., Seage III, G. R., Losina, E., Weinstein, M. C., Craven, D. E., Paltiel, A. D. (1998). The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections. JAMA 279: 130-136 [Abstract] [Full Text]  
• Jacobson, M. A., Liu, R. C.-c., Davies, D., Cohen, P. T. (1997). Human Immunodeficiency Virus Disease-Related Neutropenia and the Risk of Hospitalization for Bacterial Infection. Arch Intern Med 157: 1825-1831 [Abstract]  
• Boswell, S. L., van Gorder, M. (1997). Case 27-1997- A 38-Year-Old Man with the Acquired Immunodeficiency Syndrome and Cavitary Pulmonary Lesions. NEJM 337: 619-627 [Full Text]  
• Caumes, E., Guermonprez, G., Lecomte, C., Katlama, C., Bricaire, F. (1997). Efficacy and Safety of Desensitization With Sulfamethoxazole and Trimethoprim in 48 Previously Hypersensitive Patients Infected With Human Immunodeficiency Virus. Arch Dermatol 133: 465-469 [Abstract]  
• Moore, R. D., Chaisson, R. E. (1996). Neutropenia and latrogenic Neutrophil Dysfunction in Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome-Reply. Arch Intern Med 156: 1476-1476 [Abstract]  
• Arnott, M. A., Hay, J., Peutherer, J. F. (1996). Neutropenia and latrogenic Neutrophil Dysfunction in Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. Arch Intern Med 156: 1475-1476 [Abstract]  
• Spector, S. A., McKinley, G. F., Lalezari, J. P., Samo, T., Andruczk, R., Follansbee, S., Sparti, P. D., Havlir, D. V., Simpson, G., Buhles, W., Wong, R., Stempien, M. J., The Roche Cooperative Oral Ganciclovir Study Group, (1996). Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDS. NEJM 334: 1491-1497 [Abstract] [Full Text]  
• Owens, D. K., Nease, R. F. Jr, Harris, R. A. (1996). Cost-effectiveness of HIV Screening in Acute Care Settings. Arch Intern Med 156: 394-404 [Abstract]  
• Ioannidis, J. P. A., Cappelleri, J. C., Skolnik, P. R., Lau, J., Sacks, H. S. (1996). A Meta-analysis of the Relative Efficacy and Toxicity of Pneumocystis carinii Prophylactic Regimens. Arch Intern Med 156: 177-188 [Abstract]  
• Moore, R. D., Keruly, J. C., Chaisson, R. E. (1995). Neutropenia and Bacterial Infection in Acquired Immunodeficiency Syndrome. Arch Intern Med 155: 1965-1970 [Abstract]  
• Hirschtick, R. E., Glassroth, J., Jordan, M. C., Wilcosky, T. C., Wallace, J. M., Kvale, P. A., Markowitz, N., Rosen, M. J., Mangura, B. T., Hopewell, P. C., The Pulmonary Complications of HIV Infection Study, (1995). Bacterial Pneumonia in Persons Infected with the Human Immunodeficiency Virus. NEJM 333: 845-851 [Abstract] [Full Text]  
• Saah, A. J., Hoover, D. R., Peng, Y., Phair, J. P., Visscher, B., Kingsley, L. A., Schrager, L. K., the Multicenter AIDS Cohort Study, , Saah, A. J., Taylor, E., Margolick, J. B., Markham, R., McArthur, J., Farzadegan, H., Armenian, H., Graham, N., Phair, J. P., Chmiel, J. S., Cohen, B., Wolinsky, S., Detels, R., Visscher, B. R., Fahey, J. L., Giorgi, J. V., Dudley, J., Lee, M., Nishanian, P., Rinaldo, C. R. Jr, Ho, M., Kingsley, L. A., Gupta, P., Winkelstein, A., Mufloz, A., Peng, Y., Galai, N., Hoover, D. R., Nelson, K., Lisa, P. J., Su, S., Schrager, L., Kaslow, R. A., VanRaden, M. J., Seminara, D. (1995). Predictors for Failure of Pneumocystis carinii Pneumonia Prophylaxis. JAMA 273: 1197-1202 [Abstract]  
• Bozzette, S. A., Finkelstein, D. M., Spector, S. A., Frame, P., Powderly, W. G., He, W., Phillips, L., Craven, D., van der Horst, C., Feinberg, J., The NIAID AIDS Clinical Trials Group, (1995). A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection. NEJM 332: 693-699 [Abstract] [Full Text]  
• Powderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, M. E., Carey, J., Waskin, H., Hooton, T. M., Hyslop, N., Spector, S. A., Bozzette, S. A., The NIAID AIDS Clinical Trials Group, (1995). A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection. NEJM 332: 700-705 [Abstract] [Full Text]  
• Glass, K. C. (1994). Toward a Duty to Report Clinical Trials Accurately: The Clinical Alert and Beyond. J Law Med Ethics 22: 327-338  
• Burack, J. H., Hahn, J. A., Saint-Maurice, D., Jacobson, M. A. (1994). Microbiology of Community-Acquired Bacterial Pneumonia in Persons With and at Risk for Human Immunodeficiency Virus Type 1 Infection: Implications for Rational Empiric Antibiotic Therapy. Arch Intern Med 154: 2589-2596 [Abstract]  
• Jung, A. C., Paauw, D. S. (1994). Management of Adverse Reactions to Trimethoprim-Sulfamethoxazole in Human Immunodeficiency Virus--Infected Patients. Arch Intern Med 154: 2402-2406 [Abstract]  
• Roudier, C., Caumes, E., Rogeaux, O., Bricaire, F., Gentilini, M. (1994). Adverse Cutaneous Reactions to Trimethoprim-Sulfamethoxazole in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis carinii Pneumonia. Arch Dermatol 130: 1383-1386 [Abstract]  
• Osmond, D., Charlebois, E., Lang, W., Shiboski, S., Moss, A. (1994). Changes in AIDS Survival Time in Two San Francisco Cohorts of Homosexual Men, 1983 to 1993. JAMA 271: 1083-1087 [Abstract]  
• (1994). Prevention and treatment of Pneumocystis carinii pneumonia in patients infected with HIV. DTB 32: 12-15 [Abstract] [Full Text]  
• Girard, P.-M., Landman, R., Gaudebout, C., Olivares, R., Saimot, A. G., Jelazko, P., Gaudebout, C., Certain, A., Boue, F., Bouvet, E., Lecompte, T., Jean-Coulaud, P., The PRIO Study Group, (1993). Dapsone-Pyrimethamine Compared with Aerosolized Pentamidine as Primary Prophylaxis against Pneumocystis carinii Pneumonia and Toxoplasmosis in HIV Infection. NEJM 328: 1514-1520 [Abstract] [Full Text]  
• Weinberger, S. E. (1993). Recent Advances in Pulmonary Medicine- Second of Two Parts. NEJM 328: 1462-1470 [Full Text]  
• Martinez, E., Martinez-Chamorro, C., Martinez-Chamorro, E., Chakrabarti, J., Bornemann, M., Johnson, A. C., Denenberg, R., Grinspoon, S. K., Bilezikian, J. P. (1993). Endocrine Effects of HIV Infection. NEJM 328: 889-890 [Full Text]  
• Martin, M., Cox, P., Beck, K., Beall, G. (1993). Comparing Pneumocystis carinii Pneumonia Prophylactic Regimens-Reply. Arch Intern Med 153: 783-783 [Abstract]  
• (1992). TMP-SMX IS NOW PREFERRED FOR PCP PROPHYLAXIS. JWatch General 1992: 1-1 [Full Text]